The <scp>LGALS9</scp> / <scp>miR</scp> ‐491‐5p Axis Regulates <scp>CD8</scp> <sup>+</sup> T Cell Function and Inhibits the Progression of Gastric Cancer

Gastric cancer is a prevalent and clinically significant gastrointestinal malignancy worldwide. Gastric cancer is characterized by limited treatment efficacy and a high recurrence rate. In this study, we found that LGALS9 was highly expressed in gastric cancer and may contribute to disease progression by modulating the infiltration of CD8<sup>+</sup> T cells. Genetic knockout of LGALS9 reversed T cell function, attenuated immunosuppression, and enhanced the cytotoxic activity of T cells to kill gastric cancer cells. Furthermore, miR-491-5p was identified as a potential suppressor in gastric cancer. The microRNA miR-491-5p regulated T cell-mediated immunity by targeting and inhibiting LGALS9, which was similar to the effect of LGALS9 knockout. Overall, the key target LGALS9 and its inhibitor miR-491-5p represent promising potential for treating gastric cancer.

Authors

Institutions

Publication Details

Journal
Cancer Science
Published
2025-10-31
DOI
https://doi.org/10.1111/cas.70232
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The LGALS9 / miR ‐491‐5p Axis Regulates CD8 + T Cell Function and Inhibits the Progression of Gastric Cancer

Yingli Zhou, Honghong Fan, Wan-Hong Huang, Tao Hong et al.
Cancer Science
Cancer Immunotherapy and Biomarkers
article

The LGALS9 / miR ‐491‐5p Axis Regulates CD8 + T Cell Function and Inhibits the Progression of Gastric Cancer

Yingli Zhou, Honghong Fan, Wan-Hong Huang, Tao Hong, Wenjuan Li, Dagao Zhu, Chen Liu, Wei Lü, Liangliang Li, Wei Zheng, Jun Tao, Zhi Sun
article en

Abstract

Gastric cancer is a prevalent and clinically significant gastrointestinal malignancy worldwide. Gastric cancer is characterized by limited treatment efficacy and a high recurrence rate. In this study, we found that LGALS9 was highly expressed in gastric cancer and may contribute to disease progression by modulating the infiltration of CD8<sup>+</sup> T cells. Genetic knockout of LGALS9 reversed T cell function, attenuated immunosuppression, and enhanced the cytotoxic activity of T cells to kill gastric cancer cells. Furthermore, miR-491-5p was identified as a potential suppressor in gastric cancer. The microRNA miR-491-5p regulated T cell-mediated immunity by targeting and inhibiting LGALS9, which was similar to the effect of LGALS9 knockout. Overall, the key target LGALS9 and its inhibitor miR-491-5p represent promising potential for treating gastric cancer.

Cancer ScienceVol. 117(1)
University of Science and Technology of China (CN), The People's Hospital Tongling (CN), Anhui Provincial Hospital (CN), Tongling University (CN)
Bengbu Medical College
Openalex Percentile: Top 57%
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

The <scp>LGALS9</scp> / <scp>miR</scp> ‐491‐5p Axis Regulates <scp>CD8</scp> <sup>+</sup> T Cell Function and Inhibits the Progression of Gastric Cancer — Yingli Zhou, Honghong Fan, et al. · Cancer Science (2025) | TGRS Research Map | TGRS